Guillain–Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India

Manisha Shrivastava¹, Shah Nehal² & Navaid Seema¹

Departments of ¹Transfusion Medicine & ²Physiotherapy, Bhopal Memorial Hospital & Research Centre, Bhopal, India

Received July 7, 2014

Background & objectives: Guillain–Barre syndrome (GBS) is an autoimmune disease and a recognized cause of generalized progressive paralysis worldwide. The present study was aimed to document the clinical findings, demographics and seasonal variations amongst the patients with GBS during the hospital stay.

Methods: A retrospective analysis of 66 referred cases diagnosed as GBS was conducted. Medical records and the data related to age, sex, antecedent illness, duration of symptoms before admission, muscle power graded by the Medical Research Council scale, functional scores, details of Intensive Care Unit complications and need for ventilation were obtained. The patients were divided into four seasonal groups: S1 (spring, February to April), S2 (summer, May to July), S3 (rainy, August to October) and S4 (winter, November to January) and parameters were studied.

Results: The mean age of the patients was 40.69 yr. Forty one (62.1%) patients had a history of preceding illness. Forty nine (74.2%) patients showed quadriparesis as most common complaint. Thirty three (50%) patients were of acute inflammatory demyelinating polyneuropathy (AIDP) variant. The highest number of GBS cases (60%) was found in S1 and S2. The maximum duration of hospital stay was observed in S3 group (mean 23 days).

Interpretation & conclusions: GBS seems to affect all age groups with male preponderance. Most common antecedent event and presenting feature were flu-like illness and quadriparesis, respectively. AIDP was the most common variant. Most cases occurred from February to July (S1 and S2 group) (maximum in July) with preceding influenza and diarrhoea and maximum duration of hospital stay was observed in S3 group. Prospective studies with follow up of GBS patients need to be done to confirm findings.

Key words Acute motor axonal neuropathy - Guillain–Barre syndrome - seasonal variation
follows the flaccid paralysis typically ascending in nature evolving over a few days to a few weeks. Autonomic dysfunctions are common with usual manifestations as loss of vasomotor control with wide fluctuation in blood pressure, postural hypotension and cardiac arrhythmias. Respiratory failure and oropharyngeal weakness may require ventilatory assistance in about one-third of hospitalized patients making it a disease of vital importance for early management. It is believed that GBS may not be a single disease, but a variety of acute neuropathies with a number of related immune-mediated pathogenic mechanisms most common being endoneurial inflammation of spinal nerve roots, distal nerve segments and potential nerve entrapment sites. The reported incidence for GBS is 1-2/100,000 population and increases linearly with age, and men are about 1.5 times more affected than women. Prior infection such as upper respiratory tract infection is well-established predating event in the development of GBS by 10-14 days. Many antecedent illnesses associated with GBS have been identified including Campylobacter jejuni gastroenteritis, cytomegalovirus, Mycoplasma pneumoniae, Epstein-Barr virus and influenza virus infections. Diagnosis of GBS may be confirmed by cerebrospinal fluid (CSF) analysis and electrodiagnostic testing both of which may be normal in the early phase of GBS. The commonly recognized variants of GBS are considered as syndromes including acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor sensory axonal neuropathy (AMSAN) and Miller-Fisher syndrome. AIDP is the most prevalent form and accounts for 70-90 per cent of cases. GBS can occur in any season although seasonal variability may reflect seasonal peaks of predisposing factors such as infections. The seasonal occurrence has been described to be peaking in summer season in Asian countries. Therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVlg) are effective immunotherapies for adult and paediatric patients with GBS if given during the first few weeks of the disease along with the diligent supportive care to minimize the risk of mortality and clinical risk and eventually improving the outcomes. Physical therapy is considered as integral part of the supportive management in reducing the incidence of complications such as respiratory complications, deep vein thrombosis (DVT), pain management and delayed mobilization. The objective of this study was to assess the clinical findings, demographic and seasonal variations amongst the patients with GBS during the hospital stay in a tertiary care institute of central India.

**Material & Methods**

This study was conducted at Bhopal Memorial Hospital and Research Center (BMHRC), Bhopal, India, after obtaining the ethical approval by the Institutional Ethics Committee. In this retrospective analysis, medical records of 66 referred cases with the diagnosis of GBS admitted to BMHRC from 2002 to 2013 were reviewed and analyzed during April to June, 2014. The data related to age, sex, date of admission, antecedent illness, duration of symptoms before admission, muscle power graded by the Medical Research Council (MRC) scale, Hughes’ functional scores (F-Scores), details of Intensive Care Unit (ICU) complications if any, need for ventilation, details of investigations including CSF and electrodiagnostic analysis, complete blood profile, lipid profile, serum electrolytes, coagulation profile, blood grouping and information about TPE as therapy instituted were obtained. As per the hospital policy, all patients received TPE as the treatment of choice. Critical and supportive care comprising respiratory care including mechanical ventilation as and when required, cardiac monitoring, DVT prophylaxis, management of infections, nutritional care and physiotherapy were integral part of the treatment. Patients were classified according to MRC Manual Muscle Testing grading system (0-5) and functional grading scales: grade 0 - healthy, grade 1 - minor symptoms and signs of neuropathy, grade 2 - able to walk five min without assistance, grade 3 - able to walk five min with assistance, grade 4 - confined to bed or chair bound, and grade 5 - requiring assisted ventilation. All patients were divided into four groups based on the four seasons of the year depending on the time of their admission in the hospital. The groups were named as S1 spring season (February to April), S2 summer season (May to July), S3 rainy season (August to October) and S4 winter season (November to January) considering the geographical situation of central India.

**Statistical analysis:** The seasonal preponderance was compared by goodness of fit Chi-square test assuming a null hypothesis of no seasonal variation. The duration of hospital stay was compared by one-way ANOVA and other parameters were compared using Chi-square test.
Results

Of the 66 patients, 47 were male. The mean age of the patients was 40.69±18.8 yr. The mean ages of male and female patients were 40.82±21.19 yr (10-74 yr) and 40.36±11.34 yr (20-60 yr), respectively. The male-to-female ratio was 2.4:1. Maximum number of patients (21.2%, n=14) were in the age group of 60 yr and above. The next common age group was 20-29 yr in which 19.7 per cent (n=13) patients were seen (Table I). Nearly 62.1 per cent patients (n=41) had history of preceding illness (Table II). Flu-like illness as evidenced by fever and cough was found to be the most common antecedent event preceding GBS in 24.2 per cent patients (n=16) followed by gastroenteritis in 13.6 per cent patients (n=9). One patient each presented with the uncommon antecedent events as food poisoning and malarial fever. All patients developed neurological illness within two weeks of the onset of the symptoms (Table III). Majority of the patients were admitted to the hospital with progressive weakness in all four limbs (quadriparesis) in 74.2 per cent patients (n=49) as a common clinical feature followed by paraparesis in 25.8 per cent patients (n=17). Dysphagia and respiratory distress were noted in eight patients (12.1%) each. None of the patients were found to have bladder and bowel involvement. All patients had areflexia and two patients (3%) developed sensory involvement (Table III). All patients underwent nerve conduction velocity testing as the diagnostic testing. The majority (n=33, 50%) were found to be of AIDP followed by AMAN variants (n=29, 43.9%) and 3.0 per cent patients (n=2) were diagnosed as AMSAN (Table III).

The disease occurred sporadically throughout the year; month-wise occurrence was found to be highest in S1 and S2 groups followed by S3 group. The least number of cases were seen in S4 group. The number of GBS cases was highest in summer and spring seasons (60%) spanning from February to July with equal number of cases (n=40, S1 and S2) occurring in the two groups. However, the variants seen in the two seasons differed, S1 having preponderance of AIDP in 21.2 per cent (n=14) patients and S2 having mainly AMAN in 16.7 per cent (n=11) patients. The analysis of various parameters studied did not show any significant

| Table I. Age and sex distribution of Guillain–Barre syndrome (GBS) patients |
|------------------|------------------|------------------|
| Age (yr)         | Male (n)         | Female (n)       | Total (%) |
| 10-19            | 10               | 0                | 10 (15.2) |
| 20-29            | 9                | 4                | 13 (19.7) |
| 30-39            | 3                | 3                | 6 (9.1)   |
| 40-49            | 5                | 7                | 12 (18.2) |
| 50-59            | 7                | 4                | 11 (16.7) |
| 60 and above     | 13               | 1                | 14 (21.2) |
| Total            | 47               | 19               | 66         |

| Table II. Antecedent events observed in patients with GBS |
|-----------------|------------------|------------------|
| Illness         | Male (n)         | Female (n)       | Total (%) |
| None            | 17               | 8                | 25 (37.9) |
| Flu-like illness| 11               | 5                | 16 (24.2) |
| Diarrhoea       | 6                | 3                | 9 (13.6)  |
| Surgery         | 2                | 0                | 2 (3.0)   |
| Malarial fever  | 1                | 0                | 1 (1.5)   |
| Recurrent onset of GBS | 3 | 0 | 3 (4.5) |
| Food poisoning  | 1                | 0                | 1 (1.5)   |

| Table III. Clinical symptoms, sign and variants in patients |
|-----------------|------------------|------------------|
| Clinical symptoms/sign | Male (n) | Female (n) | Total (%) |
| Quadriplegic    | 35            | 14            | 49 (74.2) |
| Paraparesis     | 12            | 5             | 17 (25.8) |
| Cranial involvement | 5          | 3             | 8 (12.1)  |
| Bladder involvement | 0          | 0             | 0         |
| Respiratory involvement | 10        | 4             | 14 (21.2) |
| Sensory symptoms | 2             | 0             | 2 (3.0)   |
| Signs            |                |                |           |
| Areflexia        | 47            | 19            | 66 (100)  |
| Sensory abnormality | 2         | 0             | 2 (3.0)   |
| Sphincter involvement | 0        | 0             | 0         |
| Variants         |                |                |           |
| AIDP             | 27            | 5             | 33 (50)   |
| AMAN             | 17            | 12            | 29 (43.9) |
| AMSAN            | 1             | 1             | 2 (3.0)   |
| Mixed axonal variety | 1        | 1             | 2 (3.0)   |

AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; AMSAN, acute motor sensory axonal neuropathy
association with various seasons of occurrence of GBS (Table IV). Gender, motor impairment, respiratory involvement and duration of hospital stay were not significantly different between all four seasons. Almost equal number of patients of GBS got admitted to the hospital in all months except in the months of October and November. The maximum number of admissions was in July with preceding influenza and diarrhoea (Figs 1 and 2). The mean duration of hospital stay was 14 days (range 2-109). The maximum duration of hospital stay was found to be in S3 group followed by S2 group.

All patients were given TPE as a choice of the standard treatment protocol. On presentation, there was a diffuse weakness of all four extremities. The lower limbs were more severely involved than the upper limbs and distal extremities were affected more than the proximal extremities. Most of the patients were reported to be active on their F-scores before the onset of GBS. The F-score on admission and discharge were 4 and 3, respectively. About 75.75 per cent patients (n=50) improved at the time of discharge on their F-scores with mild disability. One patient required ventilator support and none of the patients died during the hospital stay.

### Discussion

In our study, there was a male preponderance (more than twice that of females) which conformed to the findings of a systematic review which reported that the incidence increased with increase in age, 50 or more years and the distribution of age existed with two peaks. In our study, progressive muscular weakness of all four limbs was the common presenting clinical feature and flu-like illness followed by gastroenteritis the most common antecedent illness, similar to that reported earlier. The most common variant of GBS was AIDP followed by AMAN. Other studies from different parts of the world have reported 80-90 per cent frequency from Europe and the USA and Indian studies reporting 48.8 to 85.2 per cent. A large study from northern India comprising 328 patients reported AIDP in 73.8 per cent patients and

### Table IV. Analysis of the parameters in accordance with seasonal variations

| Parameters | S1 (February to April) | S2 (May to July) | S3 (August to October) | S4 (November to January) | P |
|------------|------------------------|------------------|------------------------|--------------------------|---|
| Total patients | n=20 | n=20 | n=15 | n=11 | 0.327 |
| Sex (%) | | | | | |
| Male (n=47) | 16 (24.2) | 15 (22.7) | 9 (13.6) | 7 (10.6) | 0.548 |
| Female (n=19) | 4 (6.1) | 5 (7.6) | 6 (9.1) | 4 (6.1) | 0.534 |
| Diagnosis (%) | | | | | |
| AIDP (n=33) | 14 (21.2) | 8 (12.1) | 6 (9.1) | 5 (7.6) | 0.371 |
| AMAN (n=29) | 5 (7.6) | 11 (16.7) | 9 (13.6) | 4 (6.1) | |
| Duration of hospital stay (%) | | | | | |
| 1-7 days (n=25) | 4 (mean 6) (6.1) | 10 (mean 5) (15.2) | 7 (mean 5) (10.6) | 3 (mean 5) (4.5) | 0.722 |
| >7 days (n=41) | 16 (mean 11) (24.2) | 17 (mean 17) (15.2) | 8 (mean 23) (12.1) | 8 (mean 14.5) (12.1) | |
| Motor impairment on admission (%) | | | | | |
| Paraparetic (n=17) | 5 (7.6) | 3 (4.5) | 4 (6.1) | 5 (7.6) | 0.327 |
| Tetraparetic (n=49) | 15 (22.7) | 17 (25.8) | 11 (16.7) | 6 (9.1) | |
| Respiratory involvement (%) | | | | | |
| Yes (n=8) | 2 (3) | 2 (3) | 1 (1.5) | 3 (4.5) | 0.322 |
| No (n=58) | 18 (27.3) | 18 (27.3) | 14 (21.2) | 8 (12.1) | |
| Nasogastric feeding required (%) | | | | | |
| Yes (n=18) | 5 (7.6) | 4 (6.1) | 6 (9.1) | 3 (4.5) | 0.133 |
| No (n=48) | 15 (22.7) | 16 (24.2) | 9 (13.6) | 8 (12.1) | |
| Indwelling catheter (%) | | | | | |
| Yes (n=21) | 8 (12.1) | 5 (7.6) | 3 (4.5) | 5 (7.6) | 0.287 |
| No (n=45) | 12 (18.2) | 15 (22.7) | 12 (18.2) | 6 (9.1) | |

AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy

Improved at the time of discharge on their F-scores with mild disability. One patient required ventilator support and none of the patients died during the hospital stay.
better outcome compared to AMAN\textsuperscript{6}. Contrary to our findings, AMAN has been reported at a frequency of 67 per cent in a study from Bangladesh\textsuperscript{23}.

In this retrospective analysis, two peaks were found with equal number of GBS patients, one in S1 group (February to April) and the other in S2 group (May to July). Sharma \textit{et al}\textsuperscript{10} have reported maximum cases in summer (May to July), with majority of patients presenting in the month of May. The seasonal variation may be attributed to the sudden temperature differences in the seasonal conditions making certain months more prone to infections of gastrointestinal and respiratory tract, important antecedent factors of GBS. A study from Southern Iran reported significant seasonal and monthly variation with 50 per cent patients being admitted from February to June and maximum occurrence in spring and winter\textsuperscript{24}. Sriganesh \textit{et al}\textsuperscript{16} reported a higher incidence between March and August, similar to our study. Zaheer \textit{et al}\textsuperscript{9} reported a bimodal incidence of GBS during April-May (24\%) and July-August (32\%) as compared to the other months of the year. Kalita \textit{et al}\textsuperscript{6} have reported poor prognosis in AMAN variant mostly occurring in summers and complete recovery in AIDP variant which was frequent in rainy season. Our study also demonstrated that in GBS and its variants, respiratory complications (maximum in S4) and duration of hospital stay (maximum in S3) showed a seasonal variation. However, the sample size was small to establish this association clearly and retrospectively limited parameters were studied. About 12.12 per cent patients reported respiratory complications and one patient required mechanical ventilation and scored poor grade on F-score and muscle power grading of 1/5 on MCR scores. Many factors seem to be predictors for respiratory complications and thereby mechanical ventilation including progressively rapid muscular weakness, ineffective cough, bulbar involvement, rapid decrease in vital capacity\textsuperscript{16}. Critical care unit is required for the management of GBS patients with respiratory involvement\textsuperscript{25}. Hughes \textit{et al}\textsuperscript{13} reported rehabilitation as important as the immunotherapy and considered it as an integral part of the treatment of the patients with GBS. In our study, proper turning and positioning of patients to prevent bed sores and exercise therapy for maintaining muscle tone and further improvements of power were an important part of multidisciplinary care. None of the patients died during the time of the treatment and only one patient required ventilator support. All patients were advised physiotherapy treatment during the time of discharge. Early detection of the symptoms and early interventions are important factors for better prognosis of GBS\textsuperscript{26}.

The efficacies of various modalities of treatment in GBS have been a matter of discussion and debate. Hughes \textit{et al}\textsuperscript{11} reported both TPE and IVIg as equally effective treatment modalities of GBS. Another study reported similar effectiveness of TPE in the treatment of various neurological diseases including GBS\textsuperscript{27}. In this retrospective analysis, TPE was used as the standard treatment of choice in all seasons. All patients were stable and recovered well and improved in their functional grade and MRC scores at the time of discharge. No mortality related to pulmonary embolism was noted.

In this study, the outcome analysis was limited to the period of hospital stay of the patients. A further study can be designed to assess the outcome analysis of the patients on regular follow up after discharge. Further, climatic conditions might vary from region to region within the country and in other parts of the world making the observations differ. Finally, being a tertiary care centre, patients do not come directly and
are referred early for TPE mainly before developing serious complications. Thus, only one of our patients was shifted to ventilator and hence the study analyzed the non-ventilated patients in majority. However, it can serve as an adjunct to other studies done on the ventilated patients. A well-designed prospective analysis needs to be planned to study the effect of seasonal variations in the patients with GBS across the various geographic locations along with markers to establish the associations in terms of clinical features, demographics and type of immunotherapy given.

Conflicts of Interest: None.

References
1. Ropper AH, Samuels M. Adams and victor’s principles of neurology. 9th ed. New York: McGraw-Hill Medical Publishing Division; 2005. p. 1117-27.
2. Gorson KC, Ropper AH. Guillain-Barré syndrome (acute inflammatory demyelinating polyneuropathy) and related disorders. In: Katirji B, Kaminski HJ, Preston DC, et al., editors. Neuromuscular disorders in clinical practice. Boston Mass: Butterworth-Heinemann; 2002. p. 544-66.
3. Burns TM. Guillain-Barré syndrome. Semin Neurol 2008; 28: 152-67.
4. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008; 7: 939-50.
5. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333: 1374-9.
6. Kalita J, Misra UK, Goyal G, Das M. Guillain-Barré syndrome: Subtypes and predictors of outcome from India. J Peripher Nerv Syst 2014; 19: 36-43.
7. Sivadon-Tardy V, Orlikowski D, Percheron R, Sharshar T, Durand MC, Enouf V, et al. Guillain-Barré syndrome and influenza virus infection. Clin Infect Dis 2009; 48: 48-56.
8. Larsen JP, Kvåle G, Nyland H. Epidemiology of the Guillain-Barré syndrome in the county of Hordaland, Western Norway. Acta Neurol Scand 1985; 71: 43-7.
9. Zaheer M, Naeem M, Nasrullah M. Seasonal variation and sex distribution in patients with Guillain-Barré syndrome. Pak J Neurol Sci 2008; 3: 6-8.
10. Sharma G, Sood S, Sharma S. Seasonal, age & gender variation of Guillain Barre syndrome in a tertiary referral center in India. Neurosci Med 2013; 4: 23.
11. Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: A systematic review. Brain 2007; 130 (Pt 9): 2245-57.
12. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012; 7: CD001798.
13. Hughes RA, Wijdicks EF, Benson E, Cornblath DR, Hahn AF, Meythaler JM, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005; 62: 1194-8.
14. Medical Research Council. Aids to the investigation of the peripheral nervous system. London: HMSO; 1943.
15. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978; ii: 750-3.
16. Sriganesh K, Netto A, Kulkarni GB, Taly AB, Umamaheswara Rao GS. Seasonal variation in the clinical recovery of patients with Guillain Barré syndrome requiring mechanical ventilation. Neurol India 2013; 61: 349-54.
17. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32: 150-63.
18. van Koningsveld R, Rico R, Gerstenbluth I, Schmitz PI, Ang CW, Merkies IS, et al. Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean Island Curacao. Neurology 2001; 56: 1467-72.
19. Nachamkin I, Arzate Barbosa P, Ung H, Lobato C, Gonzalez Rivera A, Rodriguez P, et al. Patterns of Guillain-Barre syndrome in children: Results from a Mexican population. Neurology 2007; 69: 1665-71.
20. Gupta D, Nair M, Baheti NN, Sarma PS, Kuruvilla A; Diplomate-American Board. Electrodiagnostic and clinical aspects of Guillain-Barré syndrome: an analysis of 142 cases. J Clin Neuromuscul Dis 2008; 10: 42-51.
21. Sharma A, Lal V, Modi M, Vaishnavi C, Prabhakar S. Campylobacter jejuni infection in Guillain-Barré syndrome: A prospective case control study in a tertiary care hospital. Neurol India 2011; 59: 717-21.
22. Kannan MA, Ch RK, Jabeen SA, Mridula KR, Rao P, Borphotain R. Clinical, electrophysiological subtypes and antiganglioside antibodies in childhood Guillain-Barré syndrome. Neurol India 2011; 59: 727-32.
23. Islam Z, Jacobs BC, van Belkum A, Mohammad QD, Islam MB, Herbrink P, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 2010; 74: 581-7.
24. Borhani Haghighi A, Banihashemi MA, Zamiri N, Sabayan B, Heydari ST, Safari A, et al. Seasonal variation of Guillain-Barré syndrome admission in a large tertiary referral center in Southern Iran: A 10 year analysis. Acta Neurol Taiwan 2012; 21: 60-3.
25. Orlikowski D, Prignet H, Sharshar T, Lofaso F, Raphael JC. Respiratory dysfunction in Guillain-Barré syndrome. Neurocrit Care 2004; 1: 415-22.
26. Winer JB, Hughes RAC, Greenwood RJ, Perkin GD, Healy MJR. Prognosis in Guillain-Barré syndrome. Lancet 1985; 1: 1202-3.
27. Kaya E, Keklik M, Sencan M, Yilmaz M, Keskin A, Kiki I, et al. Therapeutic plasma exchange in patients with neurological diseases: Multicenter retrospective analysis. Transfus Apher Sci 2013; 48: 349-52.

Reprint requests: Dr Manisha Shrivastava, Department of Transfusion Medicine, Bhopal Memorial Hospital & Research Centre, Raisen Bye Pass Road, Near Karond Chowk, Bhopal 462 038, Madhya Pradesh, India
e-mail: manishasdr@gmail.com